Seattle, United States
Shape Therapeutics Inc., founded in 2018, is redefining the Biotechnology landscape with its focus on innovative RNA medicines. With its headquarters in the United States, the company positions itself at the forefront of genetic disorder solutions, merging AI with cutting-edge RNA technology to explore therapeutic options.
Their slogan, "The future of programmable RNA Medicines," encapsulates their mission of developing treatments for both rare and widespread diseases such as Alzheimer's and Parkinson's. The company's advancements in RNA editing, next-gen AAVs, and disruptive gene therapy manufacturing offer promising ventures for pharma innovators.
In its Series B funding round, ShapeTX attracted considerable attention, securing a $112.00M investment on 01 July 2021 from key investors, including Decheng Capital and Breton Capital Management. This positions them as a compelling opportunity for investors seeking impactful ventures in the biotech industry.
